Experience MRD
Join leading oncologists across Asia in transforming cancer care through cutting-edge ctDNA-MRD technology.
Join force with us, if you are:
- An oncologist who has never used K-TRACK™ and is exploring advanced ctDNA-based MRD monitoring solutions
- Practicing in: Singapore, Vietnam, Indonesia, Malaysia, Thailand, Philippines, Taiwan, or Hong Kong.
Oncologists can easily access this offer through the K-CONNECT Platform. Simply log in to your account and follow the designated pathway. Our user-friendly interface will guide you through the process, ensuring a seamless experience.
We’d love to hear your questions! Please feel free to submit any inquiries you may have about K-TRACK.
LEADING THE FUTURE OF PRECISION ONCOLOGY
Circulating tumor DNA (ctDNA) is empowering oncology with noninvasive, real-time monitoring of treatment response and minimal residual disease (MRD) detection, backed by robust clinical evidence.(1, 2) Yet, adoption barriers persist in Asia, because of lack awareness among healthcare professionals, high rate of loss to follow-up, budget constraint and insufficient evidence of clinical utility, especially in underrepresented as Asia.(3, 4)
We developed the K-TRACK portfolio to directly address these needs. Our cost-effective solution integrates both personalized tumor-informed and tumor-naïve assays. This comprehensive approach empowers you, the oncologist, to make timely, data-driven decisions for personalized treatment strategies and effective monitoring.
WHAT’S MAKE K-TRACK IS WORTH TO EXPERIENCE?
- Tailor to each patient condition: K-TRACK for Early-stage cancer patients, K-TRACK MET for Advance-stage cancer patients, and K-TRACK BO when tissue samples are unavailable.
- Comprehensive genomic profiling and minimal residual disease tracking: The initial tumor profiling results guide the selection of targeted therapies and immunotherapies, while subsequent serial ctDNA monitoring provides early prediction of recurrence and assess treatment effectiveness.
- The most clinically validated ctDNA-MRD test in Southeast Asia with both prospective clinical trial (5 cancer types, 800+ patients) and real-world data (6 cancer types, 1000+ patients)
- Trusted by leading oncologists: 6000+ ctDNA-MRD tests performed, 10+ on-going clinical trials in 15+ hospitals in 3 countries)
- CAP-Accreditation laboratory: Gene Solutions Genomics Singapore (MOH No. L/24|1577/CLB/001/242, CAP #9709518)
REFERENCES:
- Kasi PM, Fehringer G, Taniguchi H, et al: Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol 10.1200/PO.21.00181
- Krebs MG, Malapelle U, Andre F, et al: Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: A narrative review. JAMA Oncol 8:1830-1839, 2022
- Savill KMZ, Gentile D, Jeune-Smith Y, et al: Real-world utilization of ctDNA in the management of colorectal cancer. J Clin Oncol 40, 2022 (suppl 16; abstr 3075)
- Chong HY, Allotey PA, Chaiyakunapruk N: Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Med Genomics 11:94, 2018
